[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642984":3},{"organization":4,"armGroups":7,"interventions":29,"overallOfficials":34,"centralContacts":45,"locations":51,"responsibleParty":68,"collaborators":34,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":34,"eligibilityCriteria":78,"healthyVolunteers":74,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":34,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":53,"whyStopped":34,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"China-Japan Friendship Hospital","OTHER",[8,14,19,24],{"label":9,"type":10,"description":11,"interventionNames":12},"LSG-Semaglutide group","EXPERIMENTAL","Names for Surgery: Laparoscopic Sleeve Gastrectomy. Names for drugs: Semaglutide. Dosage:The starting dose was 0.25 mg per week and was subsequently titrated up based on individual patient response to a maximum maintenance dose of 2.4 mg per week.\n\nFrequency: Once per week. Duration: The treatment continued until the completion of the 6-month postoperative period.",[13],"Combination Product: LSG-Semaglutide group",{"label":15,"type":10,"description":16,"interventionNames":17},"LSG-Mazdutide group","Names for Surgery: Laparoscopic Sleeve Gastrectomy. Names for drugs:Mazdutide. Dosage:The starting dose was 2 mg per week and was subsequently titrated up based on individual patient response to a maximum maintenance dose of 6 mg per week.\n\nFrequency: Once per week. Duration: The treatment continued until the completion of the 6-month postoperative period.",[18],"Combination Product: LSG-Mazdutide group",{"label":20,"type":10,"description":21,"interventionNames":22},"LSG-Tirzepatide group","Names for Surgery: Laparoscopic Sleeve Gastrectomy. Names for drugs:Tirzepatide. Dosage:The starting dose was 2.5 mg per week and was subsequently titrated up based on individual patient response to a maximum maintenance dose of 10 mg per week.\n\nFrequency: Once per week. Duration: The treatment continued until the completion of the 6-month postoperative period.",[23],"Combination Product: LSG-Tirzepatide group",{"label":25,"type":6,"description":26,"interventionNames":27},"LSG group","Names for Surgery: Laparoscopic Sleeve Gastrectomy. Names for drugs: N\u002FA. Observation Group: Received only basic nutritional recommendation interventions after surgery.",[28],"Procedure: LSG group",[30,35,38,41],{"type":31,"name":9,"description":32,"armGroupLabels":33,"otherNames":34},"COMBINATION_PRODUCT","1. Basic Treatment Measures Within 0-30 days after sleeve gastrectomy, all patients received very low-calorie enteral nutrition powder (100 kcal\u002Fday). From 30 to 90 days post-surgery, a low-energy diet (400 kcal\u002Fday) was provided. Beyond 90 days post-surgery, a calorie-restricted diet was implemented (1,500 kcal\u002Fday for men and 1,200 kcal\u002Fday for women).\n2. In addition to laparoscopic sleeve gastrectomy and postoperative basic nutritional counseling,the LSG-Semaglutide group received subcutaneous semaglutide injections from 1 to 6 months postoperatively.The specific protocol was as follows:In the intervention group, semaglutide treatment was initiated at 1 month after LSG. The starting dose was 0.25 mg per week and was subsequently titrated up based on individual patient response to a maximum maintenance dose of 2.4 mg per week. The treatment continued until the completion of the 6-month postoperative period.",[9],null,{"type":31,"name":15,"description":36,"armGroupLabels":37,"otherNames":34},"1. Basic Treatment Measures Within 0-30 days after sleeve gastrectomy, all patients received very low-calorie enteral nutrition powder (100 kcal\u002Fday). From 30 to 90 days post-surgery, a low-energy diet (400 kcal\u002Fday) was provided. Beyond 90 days post-surgery, a calorie-restricted diet was implemented (1,500 kcal\u002Fday for men and 1,200 kcal\u002Fday for women).\n2. In addition to laparoscopic sleeve gastrectomy and postoperative basic nutritional counseling,the LSG-Mazdutide group received subcutaneous Mazdutide injections from 1 to 6 months postoperatively.The specific protocol was as follows:In the intervention group, Mazdutide treatment was initiated at 1 month after LSG. The starting dose was 2 mg per week and was subsequently titrated up based on individual patient response to a maximum maintenance dose of 6 mg per week. The treatment continued until the completion of the 6-month postoperative period.",[15],{"type":31,"name":20,"description":39,"armGroupLabels":40,"otherNames":34},"1. Basic Treatment Measures Within 0-30 days after sleeve gastrectomy, all patients received very low-calorie enteral nutrition powder (100 kcal\u002Fday). From 30 to 90 days post-surgery, a low-energy diet (400 kcal\u002Fday) was provided. Beyond 90 days post-surgery, a calorie-restricted diet was implemented (1,500 kcal\u002Fday for men and 1,200 kcal\u002Fday for women).\n2. In addition to laparoscopic sleeve gastrectomy and postoperative basic nutritional counseling,the LSG-Tirzepatide group received subcutaneous Tirzepatide injections from 1 to 6 months postoperatively.The specific protocol was as follows:In the intervention group, Tirzepatide treatment was initiated at 1 month after LSG. The starting dose was 2.5 mg per week and was subsequently titrated up based on individual patient response to a maximum maintenance dose of 10 mg per week. The treatment continued until the completion of the 6-month postoperative period.",[20],{"type":42,"name":25,"description":43,"armGroupLabels":44,"otherNames":34},"PROCEDURE","1. Basic Treatment Measures Within 0-30 days after sleeve gastrectomy, all patients received very low-calorie enteral nutrition powder (100 kcal\u002Fday). From 30 to 90 days post-surgery, a low-energy diet (400 kcal\u002Fday) was provided. Beyond 90 days post-surgery, a calorie-restricted diet was implemented (1,500 kcal\u002Fday for men and 1,200 kcal\u002Fday for women).\n2. Observation Group: Received only basic nutritional recommendation interventions after surgery.",[25],[46],{"name":47,"role":48,"phone":49,"phoneExt":34,"email":50},"Yishan Huang, Ph.D","CONTACT","+8618612256920","yuanwen0920@163.com",[52],{"facility":5,"status":53,"city":54,"state":34,"zip":34,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"RECRUITING","Beijing","China","CN",{"type":58,"coordinates":59},"Point",[60,61],116.39723,39.9075,{"lat":61,"lon":60},[64],{"name":65,"role":48,"phone":66,"phoneExt":34,"email":67},"Meng","+8618611457779","1689024958@qq.com",{"type":69,"investigatorFullName":70,"investigatorTitle":71,"investigatorAffiliation":5,"oldNameTitle":34,"oldOrganization":34},"PRINCIPAL_INVESTIGATOR","Hua Meng","Prof.","100642984","glp-1-therapy-after-bariatric-surgery-in-chinese-patients-with-obesity-100642984",false,"NCT07633639","GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity","The Efficacy and Safety of Adjuvant GLP-1 Receptor Agonist Therapy Following Metabolic Bariatric Surgery in Chinese Patients With Obesity: A Prospective, Monocentric, Stratified Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients undergoing initial laparoscopic sleeve gastrectomy (LSG).\n2. obesity:BMI ≥30 kg\u002Fm².\n3. Metabolic comorbidities: Diagnosis of metabolic syndrome or type 2 diabetes mellitus (T2DM) meeting standard criteria.\n4. Age range: 18-60 years (inclusive).\n5. Informed consent: Willing participation with documented consent.\n\nExclusion Criteria:\n\n1. Recent GLP-1RA use: Treatment with GLP-1 receptor agonists within 6 months preoperatively.\n2. Prior bariatric surgery: History of any metabolic\u002Fbariatric surgical procedure.\n3. Postoperative complications: Requiring reoperation for severe complications (e.g., hemorrhage, anastomotic leak).\n4. Non-indicated candidates: Patients not meeting standard bariatric surgery indications.\n5. Significant comorbidities:\n\n5.1Advanced hepatic\u002Frenal dysfunction (Child-Pugh C or eGFR \\\u003C30 mL\u002Fmin\u002F1.73m²). 5.2Active malignancy (except non-melanoma skin cancers). 5.3Autoimmune disorders requiring immunosuppression. 5.4Uncontrolled psychiatric conditions (e.g., active psychosis, severe depression).","ALL","18 Years","60 Years",{"count":83,"type":84},200,"ESTIMATED","INTERVENTIONAL",[87],"NA","Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with monotherapy. While bariatric surgery remains the most effective weight-loss intervention, postoperative weight regain and metabolic deterioration remain significant concerns. glucagon-like peptide-1 receptor agonists (GLP-1RA) offer distinct advantages for weight loss and metabolic control, and their combination with surgery may produce synergistic effects. This study investigates the efficacy and safety of bariatric surgery combined with adjuvant GLP-1 receptor agonist therapy for Chinese patients with obesity.",[90],"Obesity",[92,93,94,95,96,97],"obesity","Glucagon-Like Peptide-1 Receptor Agonists","Metabolic Bariatric Surgery","Semaglutide","Mazdutide","Tirzepatide","2026-06-04",{"date":100,"type":101},"2026-06-08","ACTUAL",{"date":103,"type":101},"2026-05-01",{"date":105,"type":84},"2028-05-01",{"name":5,"class":6},1]